InfuSystem (INFU) 10-Q 10 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 03, 2021
Document Information [Line Items]
Entity Central Index Key	0001337013
Entity Registrant Name	InfuSystem Holdings, Inc
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-35020
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-3341405
Entity Address, Address Line One	3851 West Hamlin Road
Entity Address, City or Town	Rochester Hills
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48309
City Area Code	248
Local Phone Number	291-1210
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	INFU
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,468,797

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 2,761	$ 9,648
Accounts receivable, net	14,693	14,720
Inventories	3,229	3,001
Other current assets	2,804	2,402
Total current assets	23,487	29,771
Medical equipment for sale or rental	1,045	1,603
Medical equipment in rental service, net of accumulated depreciation	35,769	35,611
Property & equipment, net of accumulated depreciation	4,327	4,296
Intangible assets, net	11,321	11,177
Operating lease right of use assets	4,376	4,461
Deferred income taxes	10,147	9,967
Other assets	115	105
Total assets	90,587	96,991
Current liabilities:
Accounts payable	6,553	6,779
Current portion of long-term debt	671	9,423
Other current liabilities	4,934	6,795
Total current liabilities	12,158	22,997
Long-term debt, net of current portion	31,747	29,378
Operating lease liabilities, net of current portion	3,733	3,864
Total liabilities	47,638	56,239
Stockholders’ equity:
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued	0	0
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,915,091 and 20,396,602, respectively, as of March 31, 2021, and issued and outstanding 23,816,193 and 20,297,704, respectively, as of December 31, 2020	2	2
Additional paid-in capital	86,163	84,785
Accumulated other comprehensive income	158	0
Retained deficit	(43,374)	(44,035)
Total stockholders’ equity	42,949	40,752
Total liabilities and stockholders’ equity	$ 90,587	$ 96,991

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	23,915,091	23,816,193
Common stock, shares outstanding (in shares)	20,396,602	20,297,704

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net revenues	$ 24,463	$ 21,553
Cost of revenues	9,887	8,890
Gross profit	14,576	12,663
Selling, general and administrative expenses:
Provision for doubtful accounts	(70)	285
Amortization of intangibles	1,043	1,075
Selling and marketing	2,376	2,618
General and administrative	10,354	8,652
Total selling, general and administrative	13,703	12,630
Operating income	873	33
Other expense:
Interest expense	(322)	(403)
Other expense	(69)	(19)
Income (Loss) before income taxes	482	(389)
Benefit from (provision for) income taxes	179	(29)
Net income (loss)	$ 661	$ (418)
Net income (loss) per share:
Basic (in dollars per share)	$ 0.03	$ (0.02)
Diluted (in dollars per share)	$ 0.03	$ (0.02)
Weighted average common shares outstanding:
Basic (in shares)	20,338,160	19,918,298
Diluted (in shares)	21,937,639	19,918,298
Comprehensive income (loss):
Net income (loss)	$ 661	$ (418)
Other comprehensive income:
Unrealized gain on hedges	158	0
Net comprehensive income (loss)	$ 819	$ (418)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balances (in shares) at Dec. 31, 2019	23,401				(3,518)
Balances at Dec. 31, 2019	$ 2	$ 83,699	$ (61,367)	$ 0	$ 0	$ 22,334
Stock-based shares issued upon vesting - gross (in shares)	152				0
Stock-based shares issued upon vesting - gross	$ 0	0	0	0	$ 0	0
Stock-based compensation expense	$ 0	206	0	0	$ 0	206
Employee stock purchase plan (in shares)	14				0
Employee stock purchase plan	$ 0	74	0		$ 0	74
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)	(52)				0
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	$ 0	(426)	0	0	$ 0	(426)
Common stock issued (in shares)	28				0
Common stock issued	$ 0	250	0	0	$ 0	250
Net income (loss)	$ 0	0	(418)	0	$ 0	(418)
Balances (in shares) at Mar. 31, 2020	23,543				(3,518)
Balances at Mar. 31, 2020	$ 2	83,803	(61,785)	0	$ 0	22,020
Balances (in shares) at Dec. 31, 2020	23,816				(3,518)
Balances at Dec. 31, 2020	$ 2	84,785	(44,035)	0	$ 0	40,752
Stock-based shares issued upon vesting - gross (in shares)	129				0
Stock-based shares issued upon vesting - gross	$ 0	139	0	0	$ 0	139
Stock-based compensation expense	0	1,635	0	0	0	1,635
Employee stock purchase plan	$ 0	169	0		$ 0	169
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)	(30)				0
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	$ 0	(565)	0	0	$ 0	(565)
Net income (loss)	0	0	661	0	0	661
Other comprehensive income				158		158
Balances (in shares) at Mar. 31, 2021	23,915				(3,518)
Balances at Mar. 31, 2021	$ 2	$ 86,163	$ (43,374)	$ 158	$ 0	$ 42,949

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
OPERATING ACTIVITIES
Net income (loss)	$ 661	$ (418)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Provision for doubtful accounts	(70)	285
Depreciation	2,527	2,328
Loss on disposal of and reserve adjustments for medical equipment	597	105
Loss (Gain) on sale of medical equipment	89	(1,140)
Amortization of intangible assets	1,043	1,075
Amortization of deferred debt issuance costs	96	4
Stock-based compensation	1,635	206
Deferred income taxes	(180)	9
Changes in assets - (Increase)/Decrease:
Accounts receivable	(420)	(1,628)
Inventories	(154)	(1,333)
Other current assets	(244)	(340)
Other assets	(40)	(19)
Changes in liabilities - (Decrease)/Increase:
Accounts payable and other liabilities	(2,889)	1,423
NET CASH PROVIDED BY OPERATING ACTIVITIES	2,651	557
INVESTING ACTIVITIES
Acquisition of business	(1,204)	0
Purchase of medical equipment	(2,336)	(4,007)
Purchase of property and equipment	(138)	(529)
Proceeds from sale of medical equipment, property and equipment	876	500
NET CASH USED IN INVESTING ACTIVITIES	(2,802)	(4,036)
FINANCING ACTIVITIES
Principal payments on long-term debt	(40,093)	(9,229)
Cash proceeds from long-term debt	34,000	10,468
Debt issuance costs	(386)	0
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans	(565)	(426)
Cash proceeds from stock plans	308	74
Common stock - issued	0	250
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(6,736)	1,137
Net change in cash and cash equivalents	(6,887)	(2,342)
Cash and cash equivalents, beginning of period	9,648	2,647
Cash and cash equivalents, end of period	$ 2,761	$ 305

Note 1 - Basis of Presentation,

Note 1 - Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Basis of Accounting [Text Block]	1. Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not not may 10 December 31, 2020 The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. Derivatives Accounting Policy The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company’s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to Accumulated Other Comprehensive Income in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued, the applicable amount of gain or loss included in Accumulated Other Comprehensive Income is reclassified in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities. The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settle on a net basis. The fair value of the Company’s derivative financial instruments are categorized as Level 2

Note 2 - Recent Accounting Pron

Note 2 - Recent Accounting Pronouncements and Developments	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	2. Recent Accounting Pronouncements and Developments In June 2016, No. 2016 13, 326 326 not 326 January 1, 2020, November 2019, December 15, 2022 326

Note 3 - Business Combinations

Note 3 - Business Combinations	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Business Combinations Acquisitions Accounted for Using the Purchase Method On February 3, 2021 ( FilAMed’s results of operations are included in the Company’s consolidated statements of operations from the Closing Date. Purchase Price Allocation Pursuant to FASB Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, Amount Property and equipment $ 102 Inventories 74 Medical equipment held for sale or rental 38 Intangible assets 1,186 Total - preliminary purchase price $ 1,400 On the Closing Date, the Company made an initial payment of $1.2 million. As of March 31, 2021, not

Note 4 - Revenue Recognition

Note 4 - Revenue Recognition	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4. Revenue Recognition The following table presents the Company’s disaggregated revenue by offering type (in thousands): Three Months Ended March 31, 2021 2020 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Third-Party Payer Rentals $ 12,794 52.3 % $ 11,236 52.1 % Direct Payer Rentals 8,086 33.1 % 6,859 31.8 % Product Sales 3,583 14.6 % 3,458 16.1 % Total $ 24,463 100.0 % $ 21,553 100.0 % Third-Party Payer Rentals are entirely attributed to revenues of the Integrated Therapy Services (“ITS”) segment. Product Sales are entirely attributed to revenues of the Durable Medical Equipment Services (“DME Services”) segment. For the three March 31, 2021, three March 31, 2020,

Note 5 - Medical Equipment

Note 5 - Medical Equipment	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Medical Equipment and Property Disclosure [Text Block]	5. Medical Equipment Medical equipment consisted of the following (in thousands): March 31, December 31, 2021 2020 Medical Equipment for sale or rental $ 1,107 $ 1,636 Medical Equipment for sale or rental - pump reserve (62 ) (33 ) Medical Equipment for sale or rental - net 1,045 1,603 Medical Equipment in rental service 85,080 83,411 Medical Equipment in rental service - pump reserve (1,332 ) (893 ) Accumulated depreciation (47,979 ) (46,907 ) Medical Equipment in rental service - net 35,769 35,611 Total $ 36,814 $ 37,214 Depreciation expense for medical equipment for the three March 31, 2021

Note 6 - Property and Equipment

Note 6 - Property and Equipment	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment Property and equipment consisted of the following (in thousands): March 31, 2021 December 31, 2020 Gross Assets Accumulated Depreciation Total Gross Assets Accumulated Depreciation Total Furniture, fixtures, and equipment $ 3,989 $ (2,144 ) $ 1,845 $ 3,742 $ (2,018 ) $ 1,724 Automobiles 117 (105 ) 12 117 (102 ) 15 Leasehold improvements 3,417 (947 ) 2,470 3,416 (859 ) 2,557 Total $ 7,523 $ (3,196 ) $ 4,327 $ 7,275 $ (2,979 ) $ 4,296 Depreciation expense for property and equipment was $0.2 million for both of the three March 31, 2021 March 31, 2020.

Note 7 - Intangible Assets

Note 7 - Intangible Assets	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	7. Intangible Assets The carrying amount and accumulated amortization of intangible assets consisted of the following (in thousands): March 31, 2021 December 31, 2020 Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Nonamortizable intangible assets Trade names $ 2,000 $ - $ 2,000 $ 2,000 $ - $ 2,000 Amortizable intangible assets: Trade names 23 (23 ) - 23 (23 ) - Physician and customer relationships 36,534 (29,518 ) 7,016 36,534 (28,924 ) 7,610 Software 11,230 (10,083 ) 1,147 11,230 (9,663 ) 1,567 Acquisition - FilAMed 1,186 (28 ) 1,158 - - - Total nonamortizable and amortizable intangible assets $ 50,973 $ (39,652 ) $ 11,321 $ 49,787 $ (38,610 ) $ 11,177 Amortization expense for the three March 31, 2021 five March 31, 2021 2026 and 2021 2022 2023 2024 2025 thereafter Total Amortization expense $ 3,043 $ 2,221 $ 717 $ 717 $ 537 $ 2,086 $ 9,321

Note 8 - Debt

Note 8 - Debt	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Debt On February 5, 2021, “2021 2021 The 2021 February 5, 2026. may 2021 may February 5, 2021, March 23, 2015 ( “2015 Amounts outstanding under the Revolving Facility bear interest at a variable rate equal to, at the Company’s election, a LIBO Rate for Eurodollar loans or an Alternate Base Rate for ABR loans, as defined by the 2021 2021 The 2021 ● a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 2021 four 1.00; ● a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four 1.00. The 2021 Simultaneous with the execution of the 2021 first On February 5, 2021, 2021 2015 2015 2015 2015 2021 At December 31, 2020, 2015 November 9, 2024, three December 31, 2020. December 31, 2020 30 December 31, 2020 December 31, 2020 The 2021 March 31, 2021, 2021 On April 15, 2019, third not 842. March 31, 2021 As referenced above, the Company executed and closed the 2021 first 2021, 2015 March 31, 2021 2021 December 31, 2020 2015 March 31, December 31, 2021 2020 Revolving Facility: Gross availability $ 75,000 $ 11,750 Outstanding draws (32,000 ) - Letter of credit (800 ) (800 ) Landlord reserves - (162 ) Availability on Revolving Facility $ 42,200 $ 10,788 The Company had future maturities of its long-term debt as of March 31, 2021 2021 2022 2023 2024 2025 and thereafter Total Revolving Facility $ - $ - $ - $ - $ 32,000 $ 32,000 Other financing 551 222 - - - 773 Total $ 551 $ 222 $ - $ - $ 32,000 $ 32,773 The following is a breakdown of the Company’s current and long-term debt (in thousands): March 31, 2021 December 31, 2020 Current Portion Long-Term Portion Total Current Portion Long-Term Portion Total Revolving Facility $ - $ 32,000 32,000 Revolving Facility $ - $ - $ - Term Loan - - - Term Loan 4,615 17,305 21,920 Equipment Line - - - Equipment Line 1,600 4,400 6,000 2019 Equipment Line - - - 2019 Equipment Line 2,500 7,500 10,000 Other financing 745 28 773 Other financing 725 222 947 745 32,028 32,773 9,440 29,427 38,867 Unamortized value of debt issuance costs (74 ) (281 ) (355 ) Unamortized value of debt issuance costs (17 ) (49 ) (66 ) Total $ 671 $ 31,747 $ 32,418 Total $ 9,423 $ 29,378 $ 38,801 As of March 31, 2021, 2021 March 31, 2021 March 31, 2021

Note 9 - Derivative Financial I

Note 9 - Derivative Financial Instruments and Hedging Activities	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	9. Derivative Financial Instruments and Hedging Activities During the quarter ended March 31, 2021, not The Company is exposed to interest rate risk related to its variable rate debt obligations under the 2021 February 2021, two five February 5, 2026. 30 not The table below presents the gross fair value amounts of our derivative financial instruments and the associated notional amounts designated as cash flow hedges (in thousands): March 31, 2021 (a) Balance Sheet Location Notional Fair Value Derivative Assets Derivatives designated as hedges: Cash Flow Hedges Interest Rate Swaps Other Current Assets $ 20,000 $ 158 (a) No December 31, 2020. The table below presents the effect of our derivative financial instruments designated as hedging instruments in the income statement and in AOCI: Three Months Ended March 31, 2021 (a) Gain/(Loss) on derivatives recognized in Interest Expense (b) Total Interest Expense (c) Gain/(Loss) Recognized in AOC (d) Cash Flow Hedges Interest Rate Swaps $ (10 ) $ (322 ) $ 158 (a) No three March 31, 2020 (b) Reclassified from AOCI (c) As presented in the Income Statement (d) $125 thousand expense expected to be reclassified into earnings within the next 12 The Company did not three March 31, 2021.

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Income Taxes During the three March 31, 2021, three March 31, 2020, On March 27, 2020, CARES) Act was enacted in response to the COVID- 19 CARES Act among other things, March 31, 2021. $0.7 two December 31, 2021 2022,

Note 11 - Commitments, Continge

Note 11 - Commitments, Contingencies and Litigation	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Commitments, Contingencies and Litigation From time to time in the ordinary course of its business, the Company may may not not, not not The Company is not

Note 12 - Earnings (Loss) Per S

Note 12 - Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	12. Earnings (Loss) Per Share Basic income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted income per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted income per share computations: Three Months Ended March 31, Numerator: 2021 2020 Net income (loss) (in thousands) $ 661 $ (418 ) Denominator: Weighted average common shares outstanding: Basic 20,338,160 19,918,298 Dilutive effect of common stock equivalents 1,599,479 - Diluted 21,937,639 19,918,298 Net income (loss) per share: Basic $ 0.03 $ (0.02 ) Diluted $ 0.03 $ (0.02 ) For the three March 31, 2021, not three March 31, 2020, not

Note 13 - Leases

Note 13 - Leases	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	13. Leases The Company’s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next ten not one five not not not not Payments due under the Company’s operating leases include fixed payments as well as variable payments. For the Company’s office leases, variable payments include amounts for the Company’s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company’s equipment leases, variable payments may The components of lease costs for the three March 31, 2021 2020 Three Months Ended March 31, 2021 2020 Operating lease cost $ 348 $ 424 Variable lease cost 57 112 Total lease cost $ 405 $ 536 Supplemental cash flow information and non-cash activity related to the Company’s leases are as follows (in thousands): Three Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities and ROU assets: Operating cash flow from operating leases $ 375 $ 451 ROU assets obtained in exchange for lease obligations: Operating leases $ 281 $ 118 Weighted average remaining lease terms and discount rates for the Company’s operating leases are as follows: As of March 31, 2021 2020 Years Years Weighted average remaining lease term: 6.6 7.3 Rate Rate Weighted average discount rate: 7.7 % 7.7 % Future maturities of lease liabilities as of March 31, 2021 Operating Leases 2021 $ 830 2022 1,179 2023 979 2024 949 2025 914 Thereafter 2,253 Total undiscounted lease payments 7,104 Less: Imputed interest (2,347 ) Total lease liabilities $ 4,757

Note 14 - Business Segment Info

Note 14 - Business Segment Information	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. Business Segment Information The Company’s reportable segments are organized based on service platforms, with the ITS segment reflecting higher margin rental revenues that generally include payments made by third The financial information summarized below is presented by reportable segment for the three March 31, 2021 2020: 2021 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 15,911 $ 8,552 $ - $ 24,463 Net revenues - internal - 1,446 (1,446 ) - Total net revenues 15,911 9,998 (1,446 ) 24,463 Gross profit 10,003 4,573 - 14,576 Selling , general and administrative expenses 13,703 13,703 Interest expense (322 ) (322 ) Other expense (69 ) (69 ) Benefit from income taxes 179 179 Net income $ 661 Total assets $ 62,508 $ 26,079 $ 2,000 $ 90,587 Purchases of medical equipment $ 1,621 $ 715 $ - $ 2,336 Depreciation and amortization of intangible assets $ 2,696 $ 874 $ - $ 3,570 2020 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 14,126 $ 7,427 $ - $ 21,553 Net revenues - internal - 1,238 (1,238 ) - Total net revenues 14,126 8,665 (1,238 ) 21,553 Gross profit 9,106 3,557 - 12,663 Selling, general and administrative expenses 12,630 12,630 Interest expense (403 ) (403 ) Other expense (19 ) (19 ) Provision for income taxes (29 ) (29 ) Net loss $ (418 ) Total assets $ 54,762 $ 25,916 $ 2,000 $ 82,678 Purchases of medical equipment $ 2,357 $ 1,650 $ - $ 4,007 Depreciation and amortization of intangible assets $ 2,654 $ 748 $ - $ 3,402

Note 15 - COVID-19

Note 15 - COVID-19	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Effect of Covid-19 Pandemic [Text Block]	15. COVID- 19 On March 11, 2020, 19 During the period of the pandemic, we took may 19, 19 not three March 31, 2021,

Note 16 - Subsequent Events

Note 16 - Subsequent Events	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	16. Subsequent Events On April 18, 2021, OB Healthcare ), a privately held biomedical services company, for an approximate purchase price of $6.3 million. The initial accounting for the business combination, including the estimated fair value of the assets and liabilities acquired, is incomplete as a result of the timing of the acquisition. OB Healthcare specializes in on-site repair, preventative maintenance, and device physical inventory management to hospitals and healthcare systems nationwide. The acquisition further develops and expands InfuSystem s DME segment and complements the Company s purchase of FilAMed.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Derivatives, Policy [Policy Text Block]	Derivatives Accounting Policy The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company’s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to Accumulated Other Comprehensive Income in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued, the applicable amount of gain or loss included in Accumulated Other Comprehensive Income is reclassified in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities. The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settle on a net basis. The fair value of the Company’s derivative financial instruments are categorized as Level 2

Note 3 - Business Combinations

Note 3 - Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Amount Property and equipment $ 102 Inventories 74 Medical equipment held for sale or rental 38 Intangible assets 1,186 Total - preliminary purchase price $ 1,400

Note 4 - Revenue Recognition (T

Note 4 - Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2021 2020 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Third-Party Payer Rentals $ 12,794 52.3 % $ 11,236 52.1 % Direct Payer Rentals 8,086 33.1 % 6,859 31.8 % Product Sales 3,583 14.6 % 3,458 16.1 % Total $ 24,463 100.0 % $ 21,553 100.0 %

Note 5 - Medical Equipment (Tab

Note 5 - Medical Equipment (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Medical Equipment [Table Text Block]	March 31, December 31, 2021 2020 Medical Equipment for sale or rental $ 1,107 $ 1,636 Medical Equipment for sale or rental - pump reserve (62 ) (33 ) Medical Equipment for sale or rental - net 1,045 1,603 Medical Equipment in rental service 85,080 83,411 Medical Equipment in rental service - pump reserve (1,332 ) (893 ) Accumulated depreciation (47,979 ) (46,907 ) Medical Equipment in rental service - net 35,769 35,611 Total $ 36,814 $ 37,214

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2021 December 31, 2020 Gross Assets Accumulated Depreciation Total Gross Assets Accumulated Depreciation Total Furniture, fixtures, and equipment $ 3,989 $ (2,144 ) $ 1,845 $ 3,742 $ (2,018 ) $ 1,724 Automobiles 117 (105 ) 12 117 (102 ) 15 Leasehold improvements 3,417 (947 ) 2,470 3,416 (859 ) 2,557 Total $ 7,523 $ (3,196 ) $ 4,327 $ 7,275 $ (2,979 ) $ 4,296

Note 7 - Intangible Assets (Tab

Note 7 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets [Table Text Block]	March 31, 2021 December 31, 2020 Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Nonamortizable intangible assets Trade names $ 2,000 $ - $ 2,000 $ 2,000 $ - $ 2,000 Amortizable intangible assets: Trade names 23 (23 ) - 23 (23 ) - Physician and customer relationships 36,534 (29,518 ) 7,016 36,534 (28,924 ) 7,610 Software 11,230 (10,083 ) 1,147 11,230 (9,663 ) 1,567 Acquisition - FilAMed 1,186 (28 ) 1,158 - - - Total nonamortizable and amortizable intangible assets $ 50,973 $ (39,652 ) $ 11,321 $ 49,787 $ (38,610 ) $ 11,177
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2026 and 2021 2022 2023 2024 2025 thereafter Total Amortization expense $ 3,043 $ 2,221 $ 717 $ 717 $ 537 $ 2,086 $ 9,321

Note 8 - Debt (Tables)

Note 8 - Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Line of Credit Facilities [Table Text Block]	March 31, December 31, 2021 2020 Revolving Facility: Gross availability $ 75,000 $ 11,750 Outstanding draws (32,000 ) - Letter of credit (800 ) (800 ) Landlord reserves - (162 ) Availability on Revolving Facility $ 42,200 $ 10,788
Schedule of Maturities of Long-term Debt [Table Text Block]	2021 2022 2023 2024 2025 and thereafter Total Revolving Facility $ - $ - $ - $ - $ 32,000 $ 32,000 Other financing 551 222 - - - 773 Total $ 551 $ 222 $ - $ - $ 32,000 $ 32,773
Schedule of Debt [Table Text Block]	March 31, 2021 December 31, 2020 Current Portion Long-Term Portion Total Current Portion Long-Term Portion Total Revolving Facility $ - $ 32,000 32,000 Revolving Facility $ - $ - $ - Term Loan - - - Term Loan 4,615 17,305 21,920 Equipment Line - - - Equipment Line 1,600 4,400 6,000 2019 Equipment Line - - - 2019 Equipment Line 2,500 7,500 10,000 Other financing 745 28 773 Other financing 725 222 947 745 32,028 32,773 9,440 29,427 38,867 Unamortized value of debt issuance costs (74 ) (281 ) (355 ) Unamortized value of debt issuance costs (17 ) (49 ) (66 ) Total $ 671 $ 31,747 $ 32,418 Total $ 9,423 $ 29,378 $ 38,801

Note 9 - Derivative Financial_2

Note 9 - Derivative Financial Instruments and Hedging Activities (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	March 31, 2021 (a) Balance Sheet Location Notional Fair Value Derivative Assets Derivatives designated as hedges: Cash Flow Hedges Interest Rate Swaps Other Current Assets $ 20,000 $ 158
Derivative Instruments, Gain (Loss) [Table Text Block]	Three Months Ended March 31, 2021 (a) Gain/(Loss) on derivatives recognized in Interest Expense (b) Total Interest Expense (c) Gain/(Loss) Recognized in AOC (d) Cash Flow Hedges Interest Rate Swaps $ (10 ) $ (322 ) $ 158

Note 12 - Earnings (Loss) Per_2

Note 12 - Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, Numerator: 2021 2020 Net income (loss) (in thousands) $ 661 $ (418 ) Denominator: Weighted average common shares outstanding: Basic 20,338,160 19,918,298 Dilutive effect of common stock equivalents 1,599,479 - Diluted 21,937,639 19,918,298 Net income (loss) per share: Basic $ 0.03 $ (0.02 ) Diluted $ 0.03 $ (0.02 )

Note 13 - Leases (Tables)

Note 13 - Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended March 31, 2021 2020 Operating lease cost $ 348 $ 424 Variable lease cost 57 112 Total lease cost $ 405 $ 536 Three Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities and ROU assets: Operating cash flow from operating leases $ 375 $ 451 ROU assets obtained in exchange for lease obligations: Operating leases $ 281 $ 118 As of March 31, 2021 2020 Years Years Weighted average remaining lease term: 6.6 7.3 Rate Rate Weighted average discount rate: 7.7 % 7.7 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Operating Leases 2021 $ 830 2022 1,179 2023 979 2024 949 2025 914 Thereafter 2,253 Total undiscounted lease payments 7,104 Less: Imputed interest (2,347 ) Total lease liabilities $ 4,757

Note 14 - Business Segment In_2

Note 14 - Business Segment Information (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	2021 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 15,911 $ 8,552 $ - $ 24,463 Net revenues - internal - 1,446 (1,446 ) - Total net revenues 15,911 9,998 (1,446 ) 24,463 Gross profit 10,003 4,573 - 14,576 Selling , general and administrative expenses 13,703 13,703 Interest expense (322 ) (322 ) Other expense (69 ) (69 ) Benefit from income taxes 179 179 Net income $ 661 Total assets $ 62,508 $ 26,079 $ 2,000 $ 90,587 Purchases of medical equipment $ 1,621 $ 715 $ - $ 2,336 Depreciation and amortization of intangible assets $ 2,696 $ 874 $ - $ 3,570 2020 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 14,126 $ 7,427 $ - $ 21,553 Net revenues - internal - 1,238 (1,238 ) - Total net revenues 14,126 8,665 (1,238 ) 21,553 Gross profit 9,106 3,557 - 12,663 Selling, general and administrative expenses 12,630 12,630 Interest expense (403 ) (403 ) Other expense (19 ) (19 ) Provision for income taxes (29 ) (29 ) Net loss $ (418 ) Total assets $ 54,762 $ 25,916 $ 2,000 $ 82,678 Purchases of medical equipment $ 2,357 $ 1,650 $ - $ 4,007 Depreciation and amortization of intangible assets $ 2,654 $ 748 $ - $ 3,402

Note 3 - Business Combination_2

Note 3 - Business Combinations (Details Textual) - USD ($) $ in Thousands	Feb. 03, 2021	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Payments to Acquire Businesses, Gross			$ 1,204	$ 0
FilAMed [Member]
Payments to Acquire Businesses, Gross	$ 1,200
Business Combination, Consideration Transferred, Liabilities Incurred		$ 200

Note 3 - Business Combination_3

Note 3 - Business Combinations - Purchase Price Allocation (Details) - FilAMed [Member] $ in Thousands	Feb. 03, 2021USD ($)
Property and equipment	$ 102
Inventories	74
Medical equipment held for sale or rental	38
Intangible assets	1,186
Total - preliminary purchase price	$ 1,400

Note 4 - Revenue Recognition (D

Note 4 - Revenue Recognition (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues, Total	$ 24,463	$ 21,553
Direct Payer Rentals [Member]
Revenues, Total	8,086	6,859
Direct Payer Rentals [Member] | ITS Segment [Member]
Revenues, Total	3,100	2,900
Direct Payer Rentals [Member] | DME Services Segment [Member]
Revenues, Total	$ 5,000	$ 4,000

Note 4 - Revenue Recognition -

Note 4 - Revenue Recognition - Disaggregated Revenue by Revenue Stream (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues, Total	$ 24,463	$ 21,553
Customer Concentration Risk [Member] | Third-Party Payor Rental Revenue [Member]
Percentage of total net revenues	52.30%	52.10%
Customer Concentration Risk [Member] | Direct Payer Rentals [Member]
Percentage of total net revenues	33.10%	31.80%
Customer Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]
Percentage of total net revenues	14.60%	16.10%
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member]
Percentage of total net revenues	100.00%	100.00%
Third-Party Payor Rental Revenue [Member]
Revenues, Total	$ 12,794	$ 11,236
Direct Payer Rentals [Member]
Revenues, Total	8,086	6,859
Product Sales [Member]
Revenues, Total	$ 3,583	$ 3,458

Note 5 - Medical Equipment (Det

Note 5 - Medical Equipment (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Depreciation Expense Related to Medical Equipment	$ 2.3	$ 2.1

Note 5 - Medical Equipment - Su

Note 5 - Medical Equipment - Summary of Medical Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Medical Equipment for sale or rental	$ 1,107	$ 1,636
Medical Equipment for sale or rental - pump reserve	(62)	(33)
Medical Equipment for sale or rental - net	1,045	1,603
Medical Equipment in rental service	85,080	83,411
Medical Equipment in rental service - pump reserve	(1,332)	(893)
Accumulated depreciation	(47,979)	(46,907)
Medical Equipment in rental service - net	35,769	35,611
Total	$ 36,814	$ 37,214

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Depreciation, Nonproduction	$ 0.2	$ 0.2

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Gross Assets	$ 7,523	$ 7,275
Accumulated Depreciation	(3,196)	(2,979)
Total	4,327	4,296
Furniture and Fixtures [Member]
Gross Assets	3,989	3,742
Accumulated Depreciation	(2,144)	(2,018)
Total	1,845	1,724
Automobiles [Member]
Gross Assets	117	117
Accumulated Depreciation	(105)	(102)
Total	12	15
Leasehold Improvements [Member]
Gross Assets	3,417	3,416
Accumulated Depreciation	(947)	(859)
Total	$ 2,470	$ 2,557

Note 7 - Intangible Assets (Det

Note 7 - Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Amortization of Intangible Assets, Total	$ 1,043	$ 1,075

Note 7 - Intangible Assets - Su

Note 7 - Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Amortizable intangible assets, accumulated amortization	$ (39,652)	$ (38,610)
Amortizable intangible assets, net	9,321
Total nonamortizable and amortizable intangible assets, gross assets	50,973	49,787
Total nonamortizable and amortizable intangible assets, net	11,321	11,177
Trade Names [Member]
Amortizable intangible assets, gross assets	23	23
Amortizable intangible assets, accumulated amortization	(23)	(23)
Amortizable intangible assets, net	0	0
Physician and Customer Relationships [Member]
Amortizable intangible assets, gross assets	36,534	36,534
Amortizable intangible assets, accumulated amortization	(29,518)	(28,924)
Amortizable intangible assets, net	7,016	7,610
Computer Software, Intangible Asset [Member]
Amortizable intangible assets, gross assets	11,230	11,230
Amortizable intangible assets, accumulated amortization	(10,083)	(9,663)
Amortizable intangible assets, net	1,147	1,567
Intangible Assets from FilAMed Acquisition [Member]
Amortizable intangible assets, gross assets	1,186	0
Amortizable intangible assets, accumulated amortization	(28)	0
Amortizable intangible assets, net	1,158	0
Trade Names 1 [Member]
Nonamortizable intangible assets	$ 2,000	$ 2,000

Note 7 - Intangible Assets - Ex

Note 7 - Intangible Assets - Expected Annual Amortization Expense for Intangible Assets (Details) $ in Thousands	Mar. 31, 2021USD ($)
Amortization expense, 2021	$ 3,043
Amortization expense, 2022	2,221
Amortization expense, 2023	717
Amortization expense, 2024	717
Amortization expense, 2025	537
Amortization expense, 2026 and thereafter	2,086
Amortization expense, Total	$ 9,321

Note 8 - Debt (Details Textual)

Note 8 - Debt (Details Textual) $ in Thousands	Feb. 05, 2021USD ($)	Apr. 15, 2019USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Feb. 04, 2020USD ($)
Revolving Credit Facility [Member]
Long-term Line of Credit, Total			$ 32,000	$ 0
Letters of Credit Outstanding, Amount			800	800
Line of Credit Facility, Current Borrowing Capacity			$ 75,000	11,750
The 2021 Credit Agreement [Member]
Percentage of Total Depreciation Expense	50.00%
Debt Instrument, Covenant, Minimum Fixed Coverage Ratio	1.20
Debt Instrument, Covenant, Maximum Leverage Ratio	3.50
The 2021 Credit Agreement [Member] | Eurodollar Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage			2.11%
LIBOR Rate			0.11%
The 2021 Credit Agreement [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	2.00%		2.00%
The 2021 Credit Agreement [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	2.00%		2.00%
The 2021 Credit Agreement [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	3.00%		3.00%
The 2021 Credit Agreement [Member] | ABR Loans [Member]
Debt Instrument, Interest Rate, Effective Percentage			4.25%
Lender Prime Rate			3.25%
The 2021 Credit Agreement [Member] | ABR Loans [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	1.00%		1.00%
The 2021 Credit Agreement [Member] | ABR Loans [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.00%		1.00%
The 2021 Credit Agreement [Member] | ABR Loans [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	2.00%		2.00%
The 2021 Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 75,000
Line of Credit Facility, Additional Borrowing Capacity Subject to Certain Conditions	25,000
Proceeds from Long-term Lines of Credit	30,000
The 2021 Credit Agreement [Member] | Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity	7,000
The 2015 Credit Agreement [Member]
Long-term Line of Credit, Total					$ 800
The 2015 Credit Agreement [Member] | Revolving Credit Facility [Member]
Repayments of Long-term Lines of Credit	$ 8,200
Three Term Notes Associated With the 2015 Credit Agreement [Member]
Debt Instrument, Face Amount				$ 37,900
Credit Facility [Member] | Eurodollar Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage				2.19%
LIBOR Rate				0.19%
Credit Facility [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate				2.00%
Credit Facility [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate				2.00%
Credit Facility [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate				3.00%
Credit Facility [Member] | CB Floating Rate Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage				2.25%
Credit Facility [Member] | CB Floating Rate Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate, Before Margin Rate				2.50%
Credit Facility [Member] | CB Floating Rate Loan [Member] | Greater of Prime Rate or LIBOR Plus 2.5% [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate				1.00%
Credit Facility [Member] | CB Floating Rate Loan [Member] | Greater of Prime Rate or LIBOR Plus 2.5% [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate				0.25%
Credit Facility [Member] | CB Floating Rate Loan [Member] | CB Floating Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				(1.00%)
Lender Prime Rate				3.25%
Credit Facility [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 11,800
Letters of Credit Outstanding, Amount				1,000
Line of Credit Facility, Borrowing Base				$ 15,600
Financing Agreement [Member] | Medical Equipment [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2,000
Debt Instrument, Term (Month)		36 months
Line of Credit Facility, Current Borrowing Capacity			$ 800

Note 8 - Debt - Summary of Revo

Note 8 - Debt - Summary of Revolver Based Upon Borrowers' Eligible Accounts Receivable and Inventory (Details) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Gross availability	$ 75,000	$ 11,750
Outstanding draws	(32,000)	0
Letter of credit	(800)	(800)
Landlord reserves	0	(162)
Availability on Revolving Facility	$ 42,200	$ 10,788

Note 8 - Debt - Summary of Futu

Note 8 - Debt - Summary of Future Maturities of Loans (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
2021	$ 551
2022	222
2023	0
2024	0
2025 and thereafter	32,000
Total	32,773	$ 38,867
Financing Agreement [Member]
2021	551
2022	222
2023	0
2024	0
2025 and thereafter	0
Total	773	947
Revolving Credit Facility [Member]
2021	0
2022	0
2023	0
2024	0
2025 and thereafter	32,000
Total	$ 32,000	$ 0

Note 8 - Debt - Summary of Comp

Note 8 - Debt - Summary of Company's Current and Long-term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Long-term debt, current portion, gross	$ 745	$ 9,440
Long-term debt, noncurrent portion, gross	32,028	29,427
Total, gross	32,773	38,867
Unamortized value of the debt issuance costs, current portion of long-term debt	(74)	(17)
Unamortized value of the debt issuance costs, long-term debt	(281)	(49)
Unamortized value of the debt issuance costs, Total	(355)	(66)
Current portion of long-term debt	671	9,423
Long-term debt	31,747	29,378
Total	32,418	38,801
Financing Agreement [Member]
Long-term debt, current portion, gross	745	725
Long-term debt, noncurrent portion, gross	28	222
Total, gross	773	947
Term Loan [Member]
Long-term debt, current portion, gross	0	4,615
Long-term debt, noncurrent portion, gross	0	17,305
Total, gross	0	21,920
Revolving Credit Facility [Member]
Long-term debt, current portion, gross	0	0
Long-term debt, noncurrent portion, gross	32,000	0
Total, gross	32,000	0
Equipment Line [Member]
Long-term debt, current portion, gross	0	1,600
Long-term debt, noncurrent portion, gross	0	4,400
Total, gross	0	6,000
The 2019 Equipment Line [Member]
Long-term debt, current portion, gross	0	2,500
Long-term debt, noncurrent portion, gross	0	7,500
Total, gross	$ 0	$ 10,000

Note 9 - Derivative Financial_3

Note 9 - Derivative Financial Instruments and Hedging Activities (Details Textual) - Interest Rate Swap [Member] - Designated as Hedging Instrument [Member] - Cash Flow Hedging [Member] $ in Thousands	Feb. 05, 2021	Mar. 31, 2021USD ($)
Derivative, Number of Instruments Held, Total	2
Derivative, Term of Contract (Year)	5 years
Derivative, Fixed Interest Rate	0.73%
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months		$ (125)
Derivative, Net Hedge Ineffectiveness Gain (Loss)		$ 0

Note 9 - Derivative Financial_4

Note 9 - Derivative Financial Instruments and Hedging Activities - Fair Value and Notional Amounts of Cash Flow Hedges (Details) - Cash Flow Hedging [Member] - Interest Rate Swap [Member] - Designated as Hedging Instrument [Member] - Other Current Assets [Member] $ in Thousands	Mar. 31, 2021USD ($)	[1]
Notional	$ 20,000
Fair Value Derivative Assets	$ 158
[1]	No derivative instruments existed at December 31, 2020.

Note 9 - Derivative Financial_5

Note 9 - Derivative Financial Instruments and Hedging Activities - Derivative Financial Instruments Designated As Hedging Instruments In the Income Statement and in AOCI (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Gain/(Loss) Recognized in AOC		$ 158	$ 0
Interest Rate Swap [Member]
Gain/(Loss) Recognized in AOC	[1],[2]	158
Interest Rate Swap [Member] | Interest Expense [Member]
Gain/(Loss) on derivatives recognized in Interest Expense	[2],[3]	(10)
Total Interest Expense	[2],[4]	$ (322)
[1]	$125 thousand expense expected to be reclassified into earnings within the next 12 months
[2]	No derivatives instruments existed for the three months ended March 31, 2020
[3]	Reclassified from AOCI
[4]	As presented in the Income Statement

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Expense (Benefit), Total	$ (179)	$ 29
Other Liabilities [Member]
Accrued Payroll Taxes	$ 700
Maximum [Member]
Income Tax Expense (Benefit), Total		$ 100

Note 12 - Earnings (Loss) Per_3

Note 12 - Earnings (Loss) Per Share (Details Textual) shares in Millions	3 Months Ended
	Mar. 31, 2021shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0.1

Note 12 - Earnings (Loss) Per_4

Note 12 - Earnings (Loss) Per Share - Summary of Income and Share Amounts Utilized to Calculate Basic and Diluted Net Income Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net income (loss)	$ 661	$ (418)
Weighted average common shares outstanding:
Basic (in shares)	20,338,160	19,918,298
Dilutive effect of common stock equivalents (in shares)	1,599,479	0
Diluted (in shares)	21,937,639	19,918,298
Basic (in dollars per share)	$ 0.03	$ (0.02)
Diluted (in dollars per share)	$ 0.03	$ (0.02)

Note 13 - Leases (Details Textu

Note 13 - Leases (Details Textual) - Office Leases With Renewal Options Not Reasonably Certain to Exercise [Member]	Mar. 31, 2021
Minimum [Member]
Lessee, Operating Lease, Renewal Term (Year)	1 year
Maximum [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years

Note 13 - Leases - Lease Cost (

Note 13 - Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating lease cost	$ 348	$ 424
Variable lease cost	57	112
Total lease cost	405	536
Operating cash flow from operating leases	375	451
ROU assets obtained in exchange for lease obligations: Operating leases	$ 281	$ 118
Weighted average remaining lease term: (Year)	6 years 7 months 6 days	7 years 3 months 18 days
Weighted average discount rate:	7.70%	7.70%

Note 13 - Leases - Maturities o

Note 13 - Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Mar. 31, 2021USD ($)
2021	$ 830
2022	1,179
2023	979
2024	949
2025	914
Thereafter	2,253
Total undiscounted lease payments	7,104
Less: Imputed interest	(2,347)
Total lease liabilities	$ 4,757

Note 14 - Business Segment In_3

Note 14 - Business Segment Information - Summary of Financial Information By Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Net revenues - external	$ 24,463	$ 21,553
Net revenues - internal	0	0
Total net revenues	24,463	21,553
Gross profit	14,576	12,663
Selling , general and administrative expenses	13,703	12,630
Interest expense	(322)	(403)
Other expense	(69)	(19)
Benefit from income taxes	179	(29)
Net income (loss)	661	(418)
Total assets	90,587	82,678	$ 96,991
Purchases of medical equipment	2,336	4,007
Depreciation and amortization of intangible assets	3,570	3,402
Corporate and Eliminations [Member]
Net revenues - external	0	0
Net revenues - internal	(1,446)	(1,238)
Total net revenues	(1,446)	(1,238)
Gross profit	0	0
Selling , general and administrative expenses	13,703	12,630
Interest expense	(322)	(403)
Other expense	(69)	(19)
Benefit from income taxes	179	(29)
Net income (loss)
Total assets	2,000	2,000
Purchases of medical equipment	0	0
Depreciation and amortization of intangible assets	0	0
ITS Segment [Member] | Operating Segments [Member]
Net revenues - external	15,911	14,126
Net revenues - internal	0	0
Total net revenues	15,911	14,126
Gross profit	10,003	9,106
Selling , general and administrative expenses
Interest expense
Other expense
Benefit from income taxes
Net income (loss)
Total assets	62,508	54,762
Purchases of medical equipment	1,621	2,357
Depreciation and amortization of intangible assets	2,696	2,654
DME Services Segment [Member] | Operating Segments [Member]
Net revenues - external	8,552	7,427
Net revenues - internal	1,446	1,238
Total net revenues	9,998	8,665
Gross profit	4,573	3,557
Selling , general and administrative expenses
Interest expense
Other expense
Benefit from income taxes
Net income (loss)
Total assets	26,079	25,916
Purchases of medical equipment	715	1,650
Depreciation and amortization of intangible assets	$ 874	$ 748

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) $ in Millions	Apr. 18, 2021USD ($)
Subsequent Event [Member] | Acquisition of OB Healthcare [Member]
Business Combination, Consideration Transferred, Total	$ 6.3